Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...

January 16, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December ...

The National Drug Authority (NDA) has said that they are yet to determine whether everyone who used Replenish, a ready-to-use ...

Applied Therapeutics, a clinical-stage biopharmaceutical company, is under heightened scrutiny following the issuance of a November 2024 ...

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure ...

The NDA is supported by data from the open-label, single-center phase 1/2 90-CH-0149 trial and the open-label, single-arm phase 3 09-CH-0059 study.

A Prescription Drug User Fee Act target date of June 30, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under ...

Substance abuse in the United States is one of the leading health conditions impacting millions of lives and due to many types of drug addictions ... coca leaves found in South America. Its purified ...

SANTA FE — New Mexico’s personal income tax structure will be retooled and prescription drug manufacturers will have to start disclosing pricing information to state regulators under laws set ...